Evaluation of Oral THC and CBD in Men and Women

ConditionsDrug Abuse Intoxication by Drug Impairment

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age21-55

SponsorUniversity of California, Los Angeles

About this trial

The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.

Eligibility criteria

Qualifiers

Male or non-pregnant and non-lactating females aged 21-55 years

Report weekly-monthly use of cannabis (≤1 day per week) over the past month prior to screening,

Not currently seeking treatment for their cannabis use

Have a Body Mass Index from 18.5 - 34kg/m2.

Disqualifiers

Meeting DSM-V criteria for moderate to severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine

Any other Axis I disorder

Report using other illicit drugs in the prior 4 weeks, other than cannabis.

Current use of any medications that may affect study outcomes

Trial design

Treatments tested in this trial

Placebo
THC
CBD
THC + CBD

Treatment groups

22 Participants

are divided into 4 treatment groups

Sponsors and collaborators

University of California, Los Angeles

Lead sponsor

Source ClinicalTrials.gov